PITTSBURGH – Immunotherapy drugs such as nivolumab (Opdivo) have given new hope to lung cancer and melanoma patients, some of whom are seeing remarkable response rates with the new therapies. However, progress has been slow for other cancers, including one of the deadliest, esophageal cancer.
https://www.ahn.org/news/9-5-2017/ahn-johns-hopkins-research-points-potential-way-to-effective-immunotherapy-use
AHN, Johns Hopkins Research Points Potential Way to Effective Immunotherapy Use for Esophageal Cancer Patients